

DAFTAR PUSTAKA

1. WHO (2005). Chronic obstructive pulmonary disease (COPD). <https://www.who.int/respiratory/copd/en/> - Diakses Oktober 2018.
2. WHO (2018). Prevalence of tobacco smoking. <http://www.who.int/gho/tobacco/use/en/> - Diakses Oktober 2018.
3. Global Youth Tobacco Survey (GYTS). Indonesia Report. WHO. 2014.
4. Kementerian Kesehatan Republik Indonesia. suarakan kebenaran, jangan bunuh dirimu dengan candu rokok. jakarta: Departemen kesehatan RI; 2016. <http://www.depkes.go.id/article/print/16060300002/https-2016-suarakan-kebenaran-jangan-bunuh-dirimu-dengan-candu-rokok.html>-Diakses oktober 2018.
5. Fanny W, Ko. Acute exacerbation of COPD - Ko - 2016 - Respirology - Wiley Online Library. APSR. 2016;21(7):1152-65.
6. Rosha PT, Sari F, Dewi T. Faktor-faktor yang memengaruhi kualitas hidup pasien penyakit paru obstruktif kronis. *Ber Kedokt Masy*. 2017;23(2):62-6.
7. Oemiati R. Kajian Epidemiologis Penyakit Paru. 2013;23(2):82-8.
8. GOLD. Global initiative for chronic obstructive lung disease. Trenchless Technol Roadshow. 2018.
9. Fenker DE. A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. *pulm Meds*. 2018;29(5):1-33.
10. Asizah N. Faktor Individu yang Berhubungan dengan Tindakan Merokok Mahasiswa di Universitas Hasanuddin. [skripsi]. Univ Hasanuddin; 2015.
11. Loscalzo J. HARRISON pulmonologi dan penyakit kritis. 2015. 167-177.
12. Wedzicha JA, Singh R, Mackay AJ. Acute COPD Exacerbations COPD Exacerbations. *Clin Chest Med*. 2014;35(1):157-63.
13. Debrus C, Bonhomme O, J-I C. Bronchopneumopathie chronique obstructive DÉFI EN 2017. 2017;80(1):74-80.
14. Adam RH, Medan M. Perbandingan Skor DECAF dengan Skor BAP-65 terhadap Kematian dalam Tiga Puluh Hari pada Pasien PPOK Eksaserbasi Akut di RS H . Adam Malik. 2013;48(17):7-14.
15. Montserrat-capdevila J, Godoy P, Marsal JR, Barbé F, Galván L. Risk of exacerbation in chronic obstructive pulmonary disease : a primary care retrospective cohort study. *BMC Fam Pract*. 2015;16(173):1-7.
16. Fischer BM, Voynow JA, Ghio AJ. COPD : balancing oxidants and antioxidants. Dovepress. 2015;10:261-76.
17. Permatasari N, Saad A, Christianto E. Gambaran status gizi pada pasien penyakit paru obstruktif kronik (PPOK) yang menjalani rawat jalan di RSUD Arifin Achmad Pekanbaru. *JOM FK*. 2016;3(2):1-12.

18. Ritianingsih N. Lama sakit berhubungan dengan kualitas hidup pasien penyakit paru obstruktif kronis (PPOK). *J Kesehatan Bakti Tunas Husada*. 2017;17(1):133–8.
19. AS B. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet*. 2012;370(9589):741–50.
20. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010;182(5):693–718.
21. deng X. Interactions between single nucleotide polymorphism of SERPINA1 gene and smoking in association with COPD : a case – control study. *Int J COPD*. 2017;12:259–65.
22. Saftarina F, Anggraini DI, Ridho M. Penatalaksanaan Penyakit Paru Obstruktif Kronis pada Pasien Laki-Laki Usia 66 Tahun Riwayat Perokok Aktif dengan Pendekatan Kedokteran Keluarga di Kecamatan Tanjung Sari. *Universitas Lampung*. 2017;4:143–51.
23. Bourdet S V., Williams DM. *Pharmacotherapy: A Pathophysiologic Approach*. In 2014.
24. Ambarwati, Umaroh AK, Kurniawati F, Kuswandari TD, Darojah S. Media Leaflet, Video dan Pengetahuan Siswa SD Tentang Bahaya Merokok (Studi Pada Siswa Sdn 78 Sabrang Lor Mojo songo Surakarta). *J Kesehatan Masyarakat*. 2014;10(1):7–13.
25. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald VM, et al. COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Vol. 207, *Medical Journal of Australia*. 2017. p. 436–42.
26. Hanania N, Sethi S, Koltun A, Ward J. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. *Dovepress*. 2019;14:117–27.
27. Itoh M, Tsuji T, Nemoto K, Nakamura H, Aoshiba K. Undernutrition in patients with COPD and its treatment. *Nutrients*. 2013; 5: 1316–35.
28. Hansen H, Bieler T, Beyer N, Godtfredsen N, Kallemsø T, Frølich A. COPD online-rehabilitation versus conventional COPD rehabilitation - rationale and design for a multicenter randomized controlled trial study protocol (COPRe trial). *BMC Pulmonary Medicine*. 2017; 17: 1–14.
29. Morris NR, Walsh J, Adams L, Alision J. Exercise training in COPD: What is it about intensity?. *Respirology*. 2016;21: 1185–92.
30. McCullagh BN, Comellas AP, Ballas ZK, Newell JD, Zimmerman MB, Azar AE. Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). *PLoS One*. 2017;12(2):1–13.
31. Ashley Huntsberry, PharmD, BCACP; Kimberly Won, PharmD B. Managing Chronic and Acute COPD Exacerbations. *US Pharm*. 2018;43(7):13–7.
32. Asiking W. Hubungan merokok dengan kesehatan gigi dan mulut pada pria dewasa di desa poyowa kecil kecamatan kotamobagu selatan kota kotamobagu. *Univ samratulangi ejournal Keperawatan*. 2016;4(1):2016.

33. Julina. Pengaruh persepsi dampak merokok dan fear appeal terhadap motivasi berhenti merokok mahasiswa di kota Pekanbaru. *J al-iqtishad*. 2017;1(13):35–48.
34. Salawati T, Indrawati ND, Artikel I. Analisis Kebutuhan Untuk Merancang Komik Anak “Asetaro” (Aku Akan Tetap Sehat Tanpa Asap Rokok). *J Kesehatan Masyarakat*. 2016;11(18):1–10.
35. Naser F, Medison I, Erly. Gambaran Derajat Merokok Pada Penderita PPOK di Bagian. *J Kesehatan Andalas*. 2016;5(2):306–11.
36. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. *New England Journal of Medicine*. 2016;374:1811–21.
37. PDPI (2011). Penyakit Paru Obstruktif Kronik Pedoman Diagnosis & Penatalaksanaan Di Indonesia. Perhimpunan Dokter Paru Indonesia. www.klikpdpi.com/consensus/consensus-ppok/ppok.pdf. Diakses Oktober 2018.
38. WHO (2017). Chronic obstructive pulmonary disease (COPD). World Health Organization. [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)). Diakses Oktober 2018.
39. Jaim N k. COPD Does gender really matter?. *Ing india*. 2011;28(4):258–62.
40. Johnson Jon. What is the average age for COPD?. *Medical News Today*. 2018. <https://www.medicalnewstoday.com/articles/323350.php>. Diakses Oktober 2018.
41. Alison Kleppinger JL. Prevalence of Age-Adjusted Comorbid Diseases and Implications for Survival in a COPD Population in a Primary Care Accountable Care Organization. *ATS*. 2016;193:210–20.
42. Alexopoulos. Frequency and risk factors of COPD exacerbations and hospitalizations : a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics : GOLDEN study). *Dovepress*. 2015;10:2665–74.
43. Molen HF Van Der, Groene GJ De, Hulshof CTJ. Association between Work and Chronic Obstructive Pulmonary Disease (COPD). 2018;7(335):1–8.
44. Kaplan A, Thomas M. Screening for COPD : the gap between logic and evidence. *Cross Mark*. 2017;26:1–6.
45. Li J, Sun S, Tang R, Mason TG, Tian L. Major air pollutants and risk of COPD exacerbations : a systematic review and. *Dovepress*. 2016;11:3079–91.
46. Baris serap argun. Frequency of Exacerbations and Hospitalizations in COPD Patients Who Continue to Smoke. *orginal Artic*. 2016;71(1):11–7.
47. Brandsma C, Vries M De, Costa R, Woldhuis RR. Lung ageing and COPD : is there a role for ageing in abnormal tissue repair ? *Cross Mark*. 2017;26:1–15.
48. Jarad N. Chronic obstructive pulmonary disease (COPD) and old age ? *CRD*. 2011;8(2):143–51.
49. Lin S, Ji B, Shih Y, Chen C, Chan P, Chang Y, et al. Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients. 2013;17:1638–44.
50. Garcia J. exacerbation : a prospective study. 2003;58:100–5.

51. Gompertz S, Bayley DL, Hill SL, Stockley RA, Elizabeth Q. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. 2001;56:36–41.
52. OV Z. The concept of risk factors in assessing the impact of smoking on an exacerbation of chronic obstructive pulmonary disease. КОЛЛЕКТИВ АВТОРОВ. 2015;87(3):323–36.
53. Donaldson C. COPD exacerbations ? 1 : Epidemiology. Thorax. 2006;61(2):164–8.
54. Ian D pavort, Jones PW, Burgel P. Exacerbations of COPD. Dovepress. 2016;11:21–30.
55. Indreswari YS. Faktor faktor yang berhubungan dengan eksaserbasi pada pasien penyakit paru obstruktif kronik di rumah sakit cipto mangunkusumo. Universtias Indones Libr. 2014;6–7.
56. Hague T. Both moderate and severe exacerbations accelerate physical activity decline in COPD patients. Eur Respir J. 2018;51:1–4.
57. Lola Del Puerto, Mirian Torres JAR. European Respiratory Society Annual Congress 2012. Eur Respir J. 2012;40(14):2012.
58. Footitt J, Mallia P, Durham AL, Ho WE, Telcian AG, Rosario A Del, et al. Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD. Chest. 2016;149(1):62–73.
59. Fragoso E, André S, Boleo-tomé JP, Areias V, Munhá J, Cardoso J. Understanding COPD : A vision on phenotypes , comorbidities and treatment approach. ELSEVIER. 2016;22(2):101–11.
60. Singh D. Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease Why Are the Small Airways Damaged in. trd. 2017;3536(80):317–24.
61. Higham A, Quinn AM, Cañado JED, Singh D. The pathology of small airways disease in COPD : historical aspects and future directions. Respir Res. 2019;20(49):1–11.
62. Viniol C, Vogelmeier CF. Exacerbations of COPD Exacerbation. Eur Respir J. 2018;27(3):1–9.
63. Rabe klaus f. cardio vaskular disease and COPD, Eur Respir J. 2018;27(150):1–8.
64. Wang H, Anthony D, Selemidis S, Vlahos R, Bozinovski S. Resolving Viral-Induced Secondary Bacterial Infection in COPD : A Concise Review. Frontiers (Boulder). 2018;9:1–7.
65. Jeong SH, Koh W. Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients. 2016;1857–65.
66. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2008;5:549–55.
67. Drans MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, et al. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. orginal Artic. 2017;195(3):324–30.
68. Tsiligianni I. Managing comorbidities in COPD. Int J COPD. 2015;10:95–109.
69. Westerik JAM, Metting EI, Boven JFM Van, Tiersma W, Kocks JWH, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care

patients with COPD. *respiratoryresearch*. 2017;18(31):1–17.

70. Yohannes AM, Roomi J, Waters K, Connolly MJ. Quality of life in elderly patients with COPD: measurement and predictive factors. *Respiratory Medicine*. (1998); 92:1231-6.

